Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PTC Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2022 was 1.11.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PTC Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2022.
The historical rank and industry rank for PTC Therapeutics's Cash-to-Debt or its related term are showing as below:
PTCT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.56 Med: 2.36 Max: 20548.75
Current: 1.11
During the past 11 years, PTC Therapeutics's highest Cash to Debt Ratio was 20548.75. The lowest was 0.56. And the median was 2.36.
PTC Therapeutics Cash-to-Debt Historical Data
The historical data trend for PTC Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
PTC Therapeutics Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Cash-to-Debt |
|
|
|
|
|
|
1.32 |
1.49 |
2.09 |
2.63 |
1.45 |
|
PTC Therapeutics Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.84 |
1.77 |
1.62 |
1.45 |
1.11 |
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Cash-to-Debt falls into.
PTC Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
PTC Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
PTC Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics Business Description
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
| Southwell David P |
director |
C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
| Jacobson Allan Steven |
director |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Peltz Stuart Walter |
director, officer: Chief Executive Officer |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Utter Christine Marie |
officer: SVP, Finance & CAO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Boulding Mark Elliott |
officer: Exec. VP and CLO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Hill Emily Luisa |
officer: Chief Financial Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Svoronos Dawn |
director |
C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
| Pauwels Eric |
officer: Chief Business Officer |
550 HILLS DRIVE BEDMINSTER NJ 07921 |
| Klein Matthew B. |
officer: Chief Development Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Schmertzler Michael |
director |
1300 VALLEY ROAD NEW CANAAN CT 06840 |
| Souza Marcio |
officer: Chief Operating Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Almstead Neil Gregory |
officer: Chief Technical Ops Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Reeve Emma |
director |
C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
| Steele Glenn Jr Md Phd |
director |
250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
| Zeldis Jerome B |
director |
8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
PTC Therapeutics Headlines
By Seekingalpha 2021-12-07
By Seekingalpha 2021-10-29
By Seekingalpha 2020-08-28
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.17(0.52%) Volume: 727,298 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 